Cell-secreted signals shape lymphoma identity

Seminars in Cancer Biology

Volumn 34, Issue , 2015, Pages 81-91

  Gloghini, Annunziata ^a   Bongarzone, Italia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Interstitial fluid; Lymphoma; Microenvironment; Secreted signal; Secretome

Indexed keywords

B CELL ACTIVATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 6; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAF PROTEIN; RAS PROTEIN; SCLEROPROTEIN; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE; VASCULOTROPIN; PROTEOME;

ANGIOGENESIS; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; CELLULAR SECRETION; CLASSICAL HODGKIN LYMPHOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; EXTRACELLULAR FLUID; EXTRACELLULAR MATRIX; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; INTERSTITIAL FLUID; INTRACELLULAR SIGNALING; LARGE CELL LYMPHOMA; LYMPHOID TISSUE; LYMPHOMA; NEXT GENERATION SEQUENCING; NONHODGKIN LYMPHOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEOMICS; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; CELL COMMUNICATION; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; CELL COMMUNICATION; EXOSOMES; EXTRACELLULAR FLUID; HUMANS; LYMPHOID TISSUE; LYMPHOMA; PROTEOME; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84942294437     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.02.001     Document Type: Review

References (75)

1. Campo E. Whole genome profiling and other high throughput technologies in lymphoid neoplasms - current contributions and future hopes. Mod Pathol 2013, 26(Suppl. 1):S97-S110.
2. Vaque J.P., Martinez N., Batlle-Lopez A., Perez C., Montes-Moreno S., Sanchez-Beato M., et al. B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. Haematologica 2014, 99:222-231.
3. Vaque J.P., Gomez-Lopez G., Monsalvez V., Varela I., Martinez N., Perez C., et al. PLCG1 mutations in cutaneous T-cell lymphomas. Blood 2014, 123:2034-2043.
4. Barton S., Hawkes E.A., Wotherspoon A., Cunningham D. Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?. Oncologist 2012, 17:1562-1573.
5. Menon M.P., Pittaluga S., Jaffe E.S. The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification. Cancer J 2012, 18:411-420.
6. Rossi D., Ciardullo C., Gaidano G. Genetic aberrations of signaling pathways in lymphomagenesis: revelations from next generation sequencing studies. Semin Cancer Biol 2013.
7. Staudt L.M. Therapy of DLBCL based on genomics. Hematol Oncol 2013, 31(Suppl. 1):26-28.
8. Slack G.W., Gascoyne R.D. Next-generation sequencing discoveries in lymphoma. Adv Anat Pathol 2013, 20:110-116.
9. Monboisse J.C., Oudart J.B., Ramont L., Brassart-Pasco S., Maquart F.X. Matrikines from basement membrane collagens: a new anti-cancer strategy. Biochim Biophys Acta 2014, 1840:2589-2598.
10. Munson J.M., Shieh A.C. Interstitial fluid flow in cancer: implications for disease progression and treatment. Cancer Manag Res 2014, 6:317-328.
11. Steidl C., Connors J.M., Gascoyne R.D. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011, 29:1812-1826.
12. Ribatti D., Vacca A., Dammacco F., English D. Angiogenesis and anti-angiogenesis in hematological malignancies. J Hematother Stem Cell Res 2003, 12:11-22.
13. Ruan J., Hajjar K., Rafii S., Leonard J.P. Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol 2009, 20:413-424.
14. Ma Y., Visser L., Roelofsen H., de Vries M., Diepstra A., van Imhoff G., et al. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood 2008, 111:2339-2346.
15. Wu C.C., Hsu C.W., Chen C.D., Yu C.J., Chang K.P., Tai D.I., et al. Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Mol Cell Proteomics 2010, 9:1100-1117.
16. Sauer M., Plutschow A., Jachimowicz R.D., Kleefisch D., Reiners K.S., Ponader S., et al. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol 2013, 88:113-115.
17. Ginet V., Puyal J., Rummel C., Aubry D., Breton C., Cloux A.J., et al. A critical role of autophagy in antileukemia/lymphoma effects of APO866, an inhibitor of NAD biosynthesis. Autophagy 2014, 10:603-617.
18. Barar J., Omidi Y. Targeted gene therapy of cancer: second amendment toward holistic therapy. Bioimpacts 2013, 3:49-51.
19. Baginska J., Viry E., Berchem G., Poli A., Noman M.Z., van Moer K., et al. Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proc Natl Acad Sci U S A 2013, 110:17450-17455.
20. Coupland S.E. The challenge of the microenvironment in B-cell lymphomas. Histopathology 2011, 58:69-80.
21. Burger J.A., Ghia P., Rosenwald A., Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009, 114:3367-3375.
22. Aldinucci D., Gloghini A., Pinto A., De Filippi R., Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010, 221:248-263.
23. Carbone A., Gloghini A., Cabras A., Elia G. The Germinal centre-derived lymphomas seen through their cellular microenvironment. Br J Haematol 2009, 145:468-480.
24. Lenz G., Wright G., Dave S.S., Xiao W., Powell J., Zhao H., et al. Lymphoma/leukemia molecular profiling project: stromal gene signatures in large-b-cell lymphomas. N Engl J Med 2008, 359:2313-2323.
25. Liapis K., Clear A., Owen A., Coutinho R., Greaves P., Lee A.M., et al. The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood 2013, 122:424-433.
26. de Jong D., Fest T. The microenvironment in follicular lymphoma. Best Pract Res Clin Haematol 2011, 24:135-146.
27. Dave S.S., Wright G., Tan B., Rosenwald A., Gascoyne R.D., Chan W.C., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004, 351:2159-2169.
28. Hopken U.E., Rehm A. Homeostatic chemokines guide lymphoma cells to tumor growth-promoting niches within secondary lymphoid organs. J Mol Med (Berl) 2012, 90:1237-1245.
29. Skibinski G., Skibinska A., James K. The role of hepatocyte growth factor and its receptor c-met in interactions between lymphocytes and stromal cells in secondary human lymphoid organs. Immunology 2001, 102:506-514.
30. Gloghini A., Volpe R., Carbone A. Vimentin immunostaining in fibroblastic reticulum cells within human reactive and neoplastic lymphoid follicles. Hum Pathol 1990, 21:792-798.
31. Woolf A.S., Kolatsi-Joannou M., Hardman P., Andermarcher E., Moorby C., Fine L.G., et al. Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros. J Cell Biol 1995, 128:171-184.
32. Tripodo C., Gri G., Piccaluga P.P., Frossi B., Guarnotta C., Piconese S., et al. Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol 2010, 177:792-802.
33. Gilbert L.A., Hemann M.T. Context-specific roles for paracrine IL-6 in lymphomagenesis. Genes Dev 2012, 26:1758-1768.
34. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306:2090-2093.
35. Tisi M.C., Bozzoli V., Giachelia M., Massini G., Ricerca B.M., Maiolo E., et al. Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. Leuk Lymphoma 2014, 55:270-275.
36. Medina D.J., Goodell L., Glod J., Gelinas C., Rabson A.B., Strair R.K. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor kappaB pathways. Haematologica 2012, 97:1255-1263.
37. Lied G.A., Berstad A. Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review. Scand J Immunol 2011, 73:1-7.
38. Chemnitz J.M., Driesen J., Classen S., Riley J.L., Debey S., Beyer M., et al. Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Res 2006, 66:1114-1122.
39. Munk Pedersen I., Reed J. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 2004, 45:2365-2372.
40. Caccia D., Zanetti Domingues L., Micciche F., De Bortoli M., Carniti C., Mondellini P., et al. Secretome compartment is a valuable source of biomarkers for cancer-relevant pathways. J Proteome Res 2011, 10:4196-4207.
41. Binsky I., Haran M., Starlets D., Gore Y., Lantner F., Harpaz N., et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci U S A 2007, 104:13408-13413.
42. Klasen C., Ohl K., Sternkopf M., Shachar I., Schmitz C., Heussen N., et al. MIF promotes B cell chemotaxis through the receptors CXCR4 and CD74 and ZAP-70 signaling. J Immunol 2014, 192:5273-5284.
43. Adams R.H., Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007, 8:464-478.
44. Mangi M.H., Newland A.C. Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol 2000, 111:43-51.
45. Galdiero M.R., Garlanda C., Jaillon S., Marone G., Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol 2013, 228:1404-1412.
46. Kischel P., Waltregny D., Greffe Y., Mazzucchelli G., De Pauw E., de Leval L., et al. Identification of stromal proteins overexpressed in nodular sclerosis Hodgkin lymphoma. Proteome Sci 2011, 9:63.
47. Wallentine J.C., Kim K.K., Seiler C.E., Vaughn C.P., Crockett D.K., Tripp S.R., et al. Comprehensive identification of proteins in Hodgkin lymphoma-derived Reed-Sternberg cells by LC-MS/MS. Lab Invest 2007, 87:1113-1124.
48. Gloghini A., Volpi C.C., Caccia D., Gualeni A.V., Cilia A.M., Carbone A., et al. Primary effusion lymphoma: secretome analysis reveals novel candidate biomarkers with potential pathogenetic significance. Am J Pathol 2014, 184:618-630.
49. Viry E., Paggetti J., Baginska J., Mgrditchian T., Berchem G., Moussay E., et al. Autophagy: an adaptive metabolic response to stress shaping the antitumor immunity. Biochem Pharmacol 2014.
50. Hagn M., Sontheimer K., Dahlke K., Brueggemann S., Kaltenmeier C., Beyer T., et al. Human B cells differentiate into granzyme B-secreting cytotoxic B lymphocytes upon incomplete T-cell help. Immunol Cell Biol 2012, 90:457-467.
51. Yang Z.Z., Novak A.J., Stenson M.J., Witzig T.E., Ansell S.M. Intratumoral CD4+ CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006, 107:3639-3646.
52. Yang Z.Z., Grote D.M., Ziesmer S.C., Niki T., Hirashima M., Novak A.J., et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 2012, 122:1271-1282.
53. Ansell S.M., Maurer M.J., Ziesmer S.C., Slager S.L., Habermann T.M., Link B.K., et al. Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. Am J Hematol 2012, 87:865-869.
54. Caccia D., Dugo M., Callari M., Bongarzone I. Bioinformatics tools for secretome analysis. Biochim Biophys Acta 2013, 1834:2442-2453.
55. Ahn S.M., Simpson R.J. Body fluid proteomics: prospects for biomarker discovery. Proteomics Clin Appl 2007, 1:1004-1015.
56. Raposo G., Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013, 200:373-383.
57. van Niel G., Porto-Carreiro I., Simoes S., Raposo G. Exosomes: a common pathway for a specialized function. J Biochem 2006, 140:13-21.
58. Gutzeit C., Nagy N., Gentile M., Lyberg K., Gumz J., Vallhov H., et al. Exosomes derived from Burkitt's lymphoma cell lines induce proliferation, differentiation, and class-switch recombination in B cells. J Immunol 2014, 192:5852-5862.
59. Roccaro A.M., Sacco A., Maiso P., Azab A.K., Tai Y.T., Reagan M., et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 2013, 123:1542-1555.
60. Aung T., Chapuy B., Vogel D., Wenzel D., Oppermann M., Lahmann M., et al. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATPbinding cassette transporter A3. Proc Natl Acad Sci U S A 2011, 108:15336-15341.
61. Meckes D.G., Gunawardena H.P., Dekroon R.M., Heaton P.R., Edwards R.H., Ozgur S., et al. Modulation of B-cell exosome proteins by gamma herpesvirus infection. Proc Natl Acad Sci U S A 2013, 110:E2925-E2933.
62. Wiig H., Tenstad O., Iversen P.O., Kalluri R., Bjerkvig R. Interstitial fluid: the overlooked component of the tumor microenvironment?. Fibrogenesis Tissue Repair 2010, 3:12.
63. Wiig H., Swartz M.A. Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol Rev 2012, 92:1005-1060.
64. Haslene-Hox H., Tenstad O., Wiig H. Interstitial fluid-a reflection of the tumor cell microenvironment and secretome. Biochim Biophys Acta 2013, 1834:2336-2346.
65. Haslene-Hox H., Oveland E., Berg K.C., Kolmannskog O., Woie K., Salvesen H.B., et al. A new method for isolation of interstitial fluid from human solid tumors applied to proteomic analysis of ovarian carcinoma tissue. PLoS ONE 2011, 6:e19217.
66. Gromov P., Gromova I., Olsen C.J., Timmermans-Wielenga V., Talman M.L., Serizawa R.R., et al. Tumor interstitial fluid: a treasure trove of cancer biomarkers. Biochim Biophys Acta 2013, 1834:2259-2270.
67. Halleux C.M., Takahashi M., Delporte M.L., Detry R., Funahashi T., Matsuzawa Y., et al. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 2001, 288:1102-1107.
68. Anderson L., Hunter C.L. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006, 5:573-588.
69. Whiteaker J.R., Zhao L., Abbatiello S.E., Burgess M., Kuhn E., Lin C., et al. Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol Cell Proteomics 2011, 10. M110.005645.
70. Rifai N., Gillette M.A., Carr S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24:971-983.
71. Gillet L.C., Navarro P., Tate S., Rost H., Selevsek N., Reiter L., et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics 2012, 11. O111.016717.
72. Matesanz-Isabel J., Sintes J., Llinas L., de Salort J., Lazaro A., Engel P. New B-cell CD molecules. Immunol Lett 2011, 134:104-112.
73. Bandura D.R., Baranov V.I., Ornatsky O.I., Antonov A., Kinach R., Lou X., et al. Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal Chem 2009, 81:6813-6822.
74. Qiu P., Simonds E.F., Bendall S.C., Gibbs K.D., Bruggner R.V., Linderman M.D., et al. Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotechnol 2011, 29:886-891.
75. Bendall S.C., Simonds E.F., Qiu P., Amir A.D., Krutzik P.O., Finck R., et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011, 332:687-696.